Monitoring is recommended for patients with high HBV DNA (≥107 IU/mL) and normal ALT (<40 IU/L) if there are no signs of CHBTreatment may be considered for patients >30 years of age, regardless of the severity of liver histological lesions. Patients with a family history of HCC or cirrhosis and extrahepatic manifestations can be treated. The gene discussed is GPT; the disease is hepatocellular carcinoma.